ArticleCureus2025
A Tale of Overlapping Autoimmune Serologies: Diagnosing Hydralazine-Induced Antineutrophilic Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV) Related With Isolated Pulmonary Involvement.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hydralazine is an antihypertensive that can induce immune-related adverse effects, such as hydralazine-induced lupus and hydralazine-induced antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitis (AAV). AAV involves necrotizing inflammation of small blood vessels, manifesting as fever, malaise, arthralgia, and myalgia, potentially leading to organ failure. Diagnosis includes clinical evaluation, serological testing for ANCA, and histopathological examination, confirmed by necrotizing granulomatous inflammation in affected tissues. This case report presents a rare presentation of hydralazine-induced AAV limited to the lungs, with isolated pleural involvement. A 57-year-old Caucasian male with hypertension, severe diastolic dysfunction, and end-stage renal disease undergoing dialysis presented with dyspnea, cough, and fatigue. Examination revealed bilateral lung crackles and peripheral edema. Chest computed tomography (CT) revealed a pleural effusion. Despite dialysis and thoracentesis, the patient showed no improvement, leading to pleural fluid analysis, which revealed an exudative pattern with reactive mesothelial cells. An autoimmune workup revealed elevated levels of antinuclear antibodies (ANA), anti-dsDNA, anti-histones, and ANCA. This presents a diagnostic dilemma: evolving systemic lupus erythematosus (SLE) or drug-induced vasculitis. Studies have highlighted that ANCA-positive patients may display serological features that overlap with SLE. Using the 2019 American College of Rheumatology (ACR) SLE criteria and biopsy results, we ruled out certain conditions and ultimately diagnosed the patient with chronic hydralazine-induced AAV. The patient's condition improved after hydralazine discontinuation and initiation of corticosteroid therapy. Pleural effusion can be an initial sign of AAV, and clinicians should be vigilant, especially in patients with end-stage renal disease who are unresponsive to dialysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.